BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 36593023)

  • 1. An Overview of Epigenetics in Clear Cell Renal Cell Carcinoma.
    Grammatikaki S; Katifelis H; Farooqi AA; Stravodimos K; Karamouzis MV; Souliotis K; Varvaras D; Gazouli M
    In Vivo; 2023; 37(1):1-10. PubMed ID: 36593023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic and epigenetic alterations during renal carcinogenesis.
    Arai E; Kanai Y
    Int J Clin Exp Pathol; 2010 Dec; 4(1):58-73. PubMed ID: 21228928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA Methylation Signature Reveals Cell Ontogeny of Renal Cell Carcinomas.
    Malouf GG; Su X; Zhang J; Creighton CJ; Ho TH; Lu Y; Raynal NJ; Karam JA; Tamboli P; Allanick F; Mouawad R; Spano JP; Khayat D; Wood CG; Jelinek J; Tannir NM
    Clin Cancer Res; 2016 Dec; 22(24):6236-6246. PubMed ID: 27256309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The epigenetic modifier CHD5 functions as a novel tumor suppressor for renal cell carcinoma and is predominantly inactivated by promoter CpG methylation.
    Du Z; Li L; Huang X; Jin J; Huang S; Zhang Q; Tao Q
    Oncotarget; 2016 Apr; 7(16):21618-30. PubMed ID: 26943038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma.
    Morrissey C; Martinez A; Zatyka M; Agathanggelou A; Honorio S; Astuti D; Morgan NV; Moch H; Richards FM; Kishida T; Yao M; Schraml P; Latif F; Maher ER
    Cancer Res; 2001 Oct; 61(19):7277-81. PubMed ID: 11585766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic inactivation of HOXA11, a novel functional tumor suppressor for renal cell carcinoma, is associated with RCC TNM classification.
    Wang L; Cui Y; Sheng J; Yang Y; Kuang G; Fan Y; Jin J; Zhang Q
    Oncotarget; 2017 Mar; 8(13):21861-21870. PubMed ID: 28423531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNA expression profiling of Xp11 renal cell carcinoma.
    Marchionni L; Hayashi M; Guida E; Ooki A; Munari E; Jabboure FJ; Dinalankara W; Raza A; Netto GJ; Hoque MO; Argani P
    Hum Pathol; 2017 Sep; 67():18-29. PubMed ID: 28411178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA-30a-5p
    Outeiro-Pinho G; Barros-Silva D; Aznar E; Sousa AI; Vieira-Coimbra M; Oliveira J; Gonçalves CS; Costa BM; Junker K; Henrique R; Jerónimo C
    J Exp Clin Cancer Res; 2020 Jun; 39(1):98. PubMed ID: 32487203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miR-566 functions as an oncogene and a potential biomarker for prognosis in renal cell carcinoma.
    Pan X; Quan J; Li Z; Zhao L; Zhou L; Jinling X; Weijie X; Guan X; Li H; Yang S; Gui Y; Lai Y
    Biomed Pharmacother; 2018 Jun; 102():718-727. PubMed ID: 29604591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic control of the ubiquitin carboxyl terminal hydrolase 1 in renal cell carcinoma.
    Seliger B; Handke D; Schabel E; Bukur J; Lichtenfels R; Dammann R
    J Transl Med; 2009 Oct; 7():90. PubMed ID: 19857250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression Profile of S100A2 and its Clinicopathological Significance in Renal Cell Carcinoma.
    Sugiyama T; Ozono S; Miyake H
    Anticancer Res; 2020 Nov; 40(11):6337-6343. PubMed ID: 33109571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA-384 Inhibits the Growth and Invasion of Renal Cell Carcinoma Cells by Targeting Astrocyte Elevated Gene 1.
    Song H; Rao Y; Zhang G; Kong X
    Oncol Res; 2018 Apr; 26(3):457-466. PubMed ID: 28877780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNAs Associated with Von Hippel-Lindau Pathway in Renal Cell Carcinoma: A Comprehensive Review.
    Schanza LM; Seles M; Stotz M; Fosselteder J; Hutterer GC; Pichler M; Stiegelbauer V
    Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29165391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Down-Regulation of Circular RNA_000926 Attenuates Renal Cell Carcinoma Progression through miRNA-411-Dependent CDH2 Inhibition.
    Zhang D; Yang XJ; Luo QD; Fu DL; Li ZL; Zhang P; Chong T
    Am J Pathol; 2019 Dec; 189(12):2469-2486. PubMed ID: 31476285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MiR-210 expression in tumor tissue and in vitro effects of its silencing in renal cell carcinoma.
    Redova M; Poprach A; Besse A; Iliev R; Nekvindova J; Lakomy R; Radova L; Svoboda M; Dolezel J; Vyzula R; Slaby O
    Tumour Biol; 2013 Feb; 34(1):481-91. PubMed ID: 23150176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Germline and somatic DNA methylation and epigenetic regulation of KILLIN in renal cell carcinoma.
    Bennett KL; Campbell R; Ganapathi S; Zhou M; Rini B; Ganapathi R; Neumann HP; Eng C
    Genes Chromosomes Cancer; 2011 Aug; 50(8):654-61. PubMed ID: 21584899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional and epigenetic characterization of the KRT19 gene in renal cell neoplasms.
    Paiva F; Duarte-Pereira S; Costa VL; Ramalho-Carvalho J; Patrício P; Ribeiro FR; Lobo F; Oliveira J; Jerónimo C; Henrique R
    DNA Cell Biol; 2011 Feb; 30(2):85-90. PubMed ID: 20874491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNAs in the pathogenesis of renal cell carcinoma and their diagnostic and prognostic utility as cancer biomarkers.
    Fedorko M; Pacik D; Wasserbauer R; Juracek J; Varga G; Ghazal M; Nussir MI
    Int J Biol Markers; 2016 Feb; 31(1):e26-37. PubMed ID: 26481440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma.
    Redova M; Poprach A; Nekvindova J; Iliev R; Radova L; Lakomy R; Svoboda M; Vyzula R; Slaby O
    J Transl Med; 2012 Mar; 10():55. PubMed ID: 22440013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kidney cancer is characterized by aberrant methylation of tissue-specific enhancers that are prognostic for overall survival.
    Hu CY; Mohtat D; Yu Y; Ko YA; Shenoy N; Bhattacharya S; Izquierdo MC; Park AS; Giricz O; Vallumsetla N; Gundabolu K; Ware K; Bhagat TD; Suzuki M; Pullman J; Liu XS; Greally JM; Susztak K; Verma A
    Clin Cancer Res; 2014 Aug; 20(16):4349-60. PubMed ID: 24916699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.